At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
In Brief
A Phase 1 clinical trial evaluating MVA/HIV62B vaccine, AIDSVAX B/E vaccine, and 1 other intervention for HIV Infections. Completed, enrolled 27 participants across 9 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the AIDSVAX B/E vaccine and the MVA/HIV62B vaccine in healthy, HIV-1-uninfected adults who previously received MVA/HIV62B in DNA/MVA or MVA/MVA vaccine regimens in the HVTN 205 study.
Study Details
Timeline
Interventions
1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid